News

Tiziana Life Sciences‘ intranasal spray foralumab continues to be safe and well-tolerated, with no drug-related serious side effects reported after long-term use, according to an annual report filed with the U.S. Food and Drug Administration (FDA). The company is developing foralumab for neuroinflammatory diseases such as multiple…

Quantum Biopharma has completed dosing in two toxicology studies requested by the U.S. Food and Drug Administration (FDA) that aim to support the launch of clinical studies of Lucid-MS, an experimental treatment for multiple sclerosis (MS) that’s designed to slow myelin loss. The 180-day toxicity and toxicokinetic…

Throughout 2025, the team at Multiple Sclerosis News Today brought our readers the latest advances and updates in research related to multiple sclerosis (MS). Below are the top 10 most-read news stories we published this year. We look forward to continuing to serve the MS community in 2026 and…

After months of delay, the U.S. Food and Drug Administration (FDA) has rejected Sanofi‘s application seeking approval of tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (MS). While Sanofi announced earlier this month that the decision was likely to be delayed again…

Disability progression in relapsing forms of multiple sclerosis (MS) tends to follow one of four distinct patterns, according to long-term data from more than 5,000 people with relapsing-onset MS followed in an Italian registry. The study specifically found that disability progression could generally be categorized into four patterns: minimal-worsening,…

Immutep’s experimental immunotherapy, IMP761, continues to demonstrate a favorable safety profile, along with sustained suppression of T-cell activity, immune cells that are overly active in multiple sclerosis (MS) and other autoimmune diseases. These findings are based on data from healthy people enrolled in an ongoing first-in-human Phase 1…

People exposed to higher levels of certain manufactured compounds that persist in the environment are more likely to be diagnosed with multiple sclerosis (MS), a new study reports. A higher MS risk was associated with elevated levels of PFAS, also known as “forever chemicals,” and specific metabolites of PCBs,…

Fear of a sudden relapse or a gradual worsening of MS symptoms is common among people with multiple sclerosis (MS), according to a systematic review analyzing data from more than 3,000 people with MS. Those fears are not only widespread but also closely tied to poorer mental health, greater fatigue,…

Relapses in people with relapsing-remitting multiple sclerosis (MS) may be more common in spring and summer, coinciding with warmer temperatures, low humidity, and greater fluctuations in atmospheric pressure, according to a study from Poland. Stressful life events and infections were the most frequent potential relapse triggers, the study found.

In people with progressive multiple sclerosis (MS), treatment with the antioxidant lipoic acid did not improve walking or lessen other symptoms, such as fatigue, but it did show signs of slowing brain atrophy, or the loss of brain tissue. According to the researchers, this suggests possible positive biological…

An enzyme called CEMIP could be a target for small-molecule inhibitors that aim to promote myelin repair in people with multiple sclerosis (MS) and other conditions marked by myelin loss, a study found. Researchers discovered that CEMIP, which is elevated in areas of inflammatory nerve damage in people with…

Myelin, the protective coating that helps nerve signals travel quickly and efficiently, also plays a key role in the precise timing of communication between brain cells, a new study from scientists in the Netherlands shows. In a mouse model, the researchers found that the loss of myelin disrupted the coordination…

A clinical trial testing whether music therapy can make botulinum toxin injections for spasticity more tolerable for people with multiple sclerosis (MS) and other neurological conditions is enrolling participants at Clermont-Ferrand University Hospital in France.  The study’s protocol was published in PLOS One, in a paper titled, “…

Eating more oily fish and wholegrain or wholemeal bread may help reduce a person’s risk of developing multiple sclerosis (MS), according to a new study that used data from a large U.K. database. The findings contribute to growing evidence showing that diet is “a potentially modifiable factor in MS…

Following negative Phase 3 trial results, Sanofi announced that it will not be pursuing approval of its experimental therapy tolebrutinib for primary progressive multiple sclerosis (PPMS). Meanwhile, a decision from the U.S. Food and Drug Administration (FDA) on tolebrutinib’s use in nonrelapsing secondary progressive MS (SPMS) is likely…

Children with multiple sclerosis (MS) who have more paramagnetic rim lesions (PRLs) — areas of chronic active inflammation seen on MRI scans — tend to lose more brain volume over time, a  new study found. These lesions were common in pediatric MS, a rare form of the disease…

Specific disease-modifying therapies (DMTs) significantly slow the rate of brain volume loss in adults with multiple sclerosis (MS), a benefit that is directly linked to reduced long-term disability, according to a new review. A network meta-analysis of more than 26,000 patients confirms that therapies most effective at preserving…

A signaling molecule called erythropoietin (EPO) plays a key role in allowing the immune system to distinguish the body’s own cells from foreign threats, a study found. The findings could lead to new treatments for diseases like multiple sclerosis (MS), in which the immune system inadvertently starts to attack…

Gadoquatrane, a contrast agent Bayer is developing for MRI scans, showed similar safety and pharmacokinetic (PK) profiles — meaning how a drug moves into, through, and out of the body — in both children and adults. That’s according to data from the Phase 3 QUANTI Pediatric study (NCT05915026),…

Regular physical activity was independently linked to lower disability, fatigue, and depression over time in people with multiple sclerosis (MS), a new study found. Other lifestyle factors also supported better outcomes. For example, eating a higher-quality diet was independently associated with less disability, while not smoking was…

A few months ago in Barcelona, at the annual conference of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), thousands of participants from dozens of countries convened for Patient Community Day 2025 (PCD). This annual event brings together researchers focused on multiple sclerosis (MS) and associated…

The U.S. Food and Drug Administration (FDA) has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent (siponimod), to treat people with relapsing forms of multiple sclerosis (MS). According to a company press release, the therapy is indicated for use in adults with clinically isolated syndrome,…

A Georgia State University researcher won a $1 million U.S. Department of Veterans Affairs (VA) grant to study whether a program combining cognitive training with exercise can help prevent falls in older adults with multiple sclerosis (MS). “Falls are so common — and frightening — in older adults,” Katherine…

A six-month gluten-free diet significantly eased disability and supported a healthier body composition in women with relapsing-remitting multiple sclerosis (RRMS), a new small study found. The findings support growing evidence linking the gut-brain axis and metabolic inflammation to MS, and suggest that a gluten-free diet may be a promising dietary…

Octave Bioscience is entering into a collaboration with Quest Diagnostics to expand access to its multiple sclerosis disease activity (MSDA) test, which uses data from a set of blood biomarkers to measure how active a patient’s disease is in people with multiple sclerosis (MS). Although the MSDA…

People who drink coffee may have a more than 20% lower risk of developing multiple sclerosis (MS) compared with those who do not, according to a new analysis of published studies that pooled data from more than 4,500 participants from seven countries. “These results suggest that coffee consumption might…

Lynk Pharmaceuticals has received the green light from the U.S. Food and Drug Administration (FDA) to begin clinical trials of its investigational oral therapy LNK01006, which is being developed for multiple sclerosis (MS) and other neuroinflammatory diseases. “We look forward to advancing this promising molecule into human clinical…

For most people with multiple sclerosis (MS), the use of disease-modifying therapies, or DMTs, does not affect their perceived pain, according to a survey-based study in Australia. As few as one-third of MS patients who had ever used DMTs reported a change in pain, while one-eighth of those…

Adherence to either the Mediterranean or the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets was associated with better performance in certain areas of thinking and memory among people with multiple sclerosis (MS), a U.K. study suggests. The Mediterranean diet reflects foods traditionally eaten in countries around the Mediterranean Sea.

Aquatic therapy significantly eased fatigue and improved balance in multiple sclerosis (MS) patients in a clinical trial in Greece, outperforming results from a control group who participated in a conventional physiotherapy program. “Our work suggests that incorporating [aquatic therapy] into MS care can meaningfully alleviate fatigue and balance deficits,…